China’s Shanghai Junshi Biosciences Co., Ltd (SHA: 688180, HKG: 1877) announced plans to raise up to RMB 3.97 billion (USD 572 million) via private placement, with proceeds allocated to novel drug R&D and construction of its headquarters and R&D facilities. The move underscores the firm’s ambition to accelerate pipeline development and expand infrastructure.
Funding Details
The capital raise will support clinical and pre-clinical studies for Junshi’s innovative drugs globally, including toripalimab (PD-1 inhibitor Tuoyi), JS004 (a first-in-class BTLA-specific monoclonal antibody), and JS111. JS004, targeting advanced solid tumors, is in Phase II trials in the U.S. and China after securing IND approvals in both markets.
Drug Development Focus
- Toripalimab: Junshi’s flagship PD-1 inhibitor, approved in China for multiple cancer indications.
- JS004: A novel BTLA antibody designed to overcome immune evasion in tumors, with ongoing Phase II trials.
- JS111: An investigational asset targeting unmet needs in oncology and immunology.
Strategic Expansion
The funding will also fuel construction of Junshi’s headquarters and R&D base, enhancing its capacity for large-scale clinical trials and global collaborations. The company aims to leverage its growing pipeline to establish a leadership position in immuno-oncology and beyond.-Fineline Info & Tech
